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Abstract
Considerable evidence has now accumulated for tumour-associa-
ted macrophages stimulating key aspects of tumour progression,
including the proliferation, survival and metastasis of tumour cells,
tumour angiogenesis and suppression of the anti-tumour functions
of other immune effectors at the tumour site. Tumour micro-
environmental factors such as hypoxia have profound, direct
effects on these cells, stimulating many of their pro-tumour
functions. Hypoxia also does so indirectly by stimulating the
release of the cytokine angiopoietin-2 from tumour cells and
tumour blood vessels. This in turn then recruits Tie-2-expressing
monocytes into tumours from the bloodstream and inhibits their
production of anti-apoptotic and anti-angiogenic cytokines.
Role of tumour-associated macrophages in
tumour progression
Two different approaches – the use of various transgenic
mouse models and the analysis of human tumours – have
demonstrated a close link between the activity of tumour-
associated macrophages (TAMs) and tumour progression
[1,2]. TAMs are abundant in most forms of solid tumour,
where they often display a relatively immature phenotype and
are positively correlated with tumour angiogenesis and/or
progression (reviewed in [3]). Pollard’s group crossed PyMT-
MMTV mice (which spontaneously develop mammary tumours)
with the transgenic op/op mouse model lacking the gene for
colony-stimulating factor-1, a crucial growth factor for macro-
phages and their precursors from the bone marrow, namely
blood monocytes. The tumours that developed in these
macrophage-depleted mice showed a slower rate of
progression to malignancy and formed far fewer metastases
in the lungs than those in non-macrophage-depleted mice [1].
Moreover, Pollard’s group recently characterised the
development of the vasculature in PyMT-MMTV tumours
during progression to malignancy and showed that the onset
of the ‘angiogenic switch’ (the formation of the high-density
vessel network associated with the transition to malignancy)
was regulated by TAMs. Preinvasive mammary lesions in
op/op mice exhibited both a delayed angiogenic switch and
transition to malignancy, whereas genetic restoration of the
macrophage population in tumours reversed this [4].
Although these studies suggest that TAMs have a key role in
promoting tumour angiogenesis, progression to malignancy
and metastasis, they have yet to be confirmed in similar
studies with other macrophage-depleted, transgenic mouse
tumour models.
However, these data accord well with our finding that high
numbers of TAMs correlate with increased tumour angio-
genesis, lymph node status and reduced survival of breast
cancer patients [5]. Moreover, we showed that TAMs in
breast carcinomas express numerous tumour-promoting
factors such as the important mitogen epidermal growth
factor [6] and the pro-angiogenic cytokine vascular endo-
thelial growth factor (VEGF) [7]. TAMs have also been shown
to release a variety of other cytokines and enzymes known to
promote tumour invasion, angiogenesis and metastasis [3,8].
Recent studies indicate that when macrophages migrate into
tumours they downregulate their expression of the potent
anti-angiogenic cytokine IL-12 [9].
These findings  have prompted investigations into how the
tumour microenvironment ‘educates’ macrophages to perform
these pro-tumour activities. Here we outline the important role
of tumour hypoxia in this, both in the form of a direct effect on
the expression of pro-tumour genes by TAMs, and indirectly
by upregulating the pro-angiogenic cytokine angiopoietin-2
(Ang-2), which in turn has profound effects on TAM function.
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Effect of tumour hypoxia on
tumour-associated macrophages
The vasculature in tumours is often disorganised, chaotic and
prone to collapse. This results in the formation of multiple
areas of inadequate vascular perfusion and hypoxia in solid
tumours [10]. For some time it has been known that hypoxia
alters the function of tumour cells, stimulating them to release
pro-angiogenic factors, de-differentiate, become resistant to
most forms of chemotherapy and metastasise [11]. We and
others have shown that hypoxia also has marked effects on
macrophage function in tumours.
A subpopulation of TAMs gather in hypoxic, avascular and/or
necrotic sites in breast tumours [5,7,12], possibly as a result
of the release of such macrophage chemoattractants as
endothelial-monocyte-activating polypeptide (EMAP) II,
endothelin-2 and VEGF by tumour cells in these sites
(reviewed in [13]). Furthermore, because macrophages are
phagocytes they may also be attracted into hypoxic, peri-
necrotic areas along a trail of necrotic debris emanating from
these areas. Indeed, we have shown recently that necrotic
debris generated from the repeated freezing and thawing of a
human breast tumour cell line (T47D) acts as a powerful
chemoattractant for human macrophages in vitro and that this
was mediated in part by their detection of necrotic debris by
cell surface receptors called class A scavenger receptors (R
Hughes, C Murdoch, S Tazzyman and CE Lewis, unpublished
observations). Once they reach a hypoxic area, it seems from
the work of Balkwill and colleagues [14] that hypoxia then
inhibits macrophage migration, immobilising them in these
areas. The interplay of these microenvironmental cues on
TAM migration is illustrated in Figure 1.
Exposure to hypoxia in these sites stimulates TAMs to acquire
a pro-angiogenic phenotype. For example, it stimulates them
to express VEGF [7] and the pro-invasive and pro-angiogenic
enzyme matrix metalloproteinase-7 [15], as demonstrated in
vitro and in hypoxic areas of breast tumours. Furthermore, we
recently demonstrated that when human macrophages
infiltrate into the hypoxic centre of human breast tumour
spheroids  in vitro, they release VEGF and significantly
enhance the angiogenic potential of spheroids when they are
subsequently implanted into dorsal skin window chambers in
nude mice and observed after 3 days [16]. This accords with
the finding that hypoxia stimulates primary human macro-
phages to upregulate more than 30 other pro-angiogenic
genes [17]. The impressive array of pro-tumour cytokines,
enzymes and cell surface receptors expressed by macro-
phages in hypoxia are summarised in Figure 2 and reviewed
in [18].
Hypoxia-induced gene expression in tumour cells is known to
involve the nuclear accumulation of the transcription factors
hypoxia-inducible transcription factor (HIF)-1 and HIF-2,
which bind to cognate binding sequences in or near the
promoters of target genes. Macrophages upregulate both
HIFs when exposed to hypoxia in vitro or inside human
tumours [15,19]. Furthermore, high expression of one of
these (HIF-2) in TAMs in breast carcinomas was correlated
with increased tumour vascularity, presumably because of the
upregulation by these cells of HIF target genes such as that
encoding the pro-angiogenic cytokine VEGF [20]. However,
the effects of hypoxia on TAMs are linked to the differentiation
status of macrophages: our studies indicate that, unlike fully
differentiated macrophages, their precursors, human
monocytes from peripheral blood, fail to upregulate either HIF
in tumour levels of hypoxia. Rather, they upregulate other
hypoxia-induced transcription factors such as Ets-1, ATF-4
(activating transcription factor-4), Egr-1 (early growth
response-1), C/EBPβ (CCAAT-enhancer-binding protein β)
and nuclear factor (NF)-κB [21]. This finding was confirmed
by a recent report showing that a human monocytic cell line
required exposure to a chemical inducer of differentiation
before it could upregulate HIF-1 in response to hypoxia [22].
Because several recent studies have shown that TAMs
exhibit a relatively immature phenotype in tumours [23], the
exact contribution of these various transcription factors to the
Figure 1
Mechanisms responsible for the accumulation of tumour-associated
macrophages in hypoxic areas of solid tumours. A microenronment
within a human tumour is shown containing two blood vessels and a
hypoxic area (white) that has formed because it is more than 100 to
150 µm from either vessel – the critical distance for oxygenation in
such tissues. Monocytes (M) pass through these vessels and are
recruited into tumours by the release of the monocyte
chemoattractants CCL2, 3, 4, 5 and 8 and colony-stimulating factor-1
(CSF-1) by the tumour. Once monocytes have moved across the
tumour vasculature, many are attracted into hypoxic areas by the
hypoxia-induced release of other monocyte attractants such as
vascular endothelial growth factor (VEGF), endothelin-2 (ET-2) and
endothelial-monocyte-activating polypeptide (EMAP) II. These innate
cells may also be attracted into sites experiencing chronic hypoxia (and
thus cell death) along a trail of necrotic debris emanating from these
areas. Hypoxia then acts directly on macrophages to immobilise them
and also via the upregulation of macrophage migration inhibitory factor
(MIF) by tumour cells, which has a similar effect on macrophage
migration (reviewed in [13]).Page 3 of 4
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The cytokines Ang-1 and Ang-2 regulate processes such as
angiogenesis by binding specifically to the receptor tyrosine
kinase Tie2/Tek on endothelial cells. Ang-1 acts as a Tie-2
agonist to promote and stabilise mature vessels by promoting
interactions between endothelial cells, pericytes, basement
membrane and surrounding extracellular matrix. Conversely,
Ang-2, the predominant form of angiopoietin in malignant
tissues, has been shown to be a functional antagonist of
Ang-1 and binds competitively to Tie-2, antagonising the
stabilising effect of Ang-1, resulting in an overall destabilisa-
tion of existing vessels (reviewed in [24]). In the presence of
VEGF these destabilised vessels undergo angiogenic
changes and sprout to form new vessels. Thus, angiogenesis
is controlled by a dynamic balance between vessel
stabilisation and growth, mediated by VEGF, Ang-1 and
Ang-2. It has been shown that breast carcinomas express
higher levels of Ang-2 than of Ang-1 and that this is
correlated with high levels of VEGF expression and tumour
angiogenesis [25].
However, Ang-2 has recently been shown to have agonistic
functions and to be capable of activating Tie-2 to stimulate
endothelial cell migration and tubule formation in vitro [26].
Thus, Ang-2 seems to possess both agonist and antagonist
functions when acting on endothelial cells.
Until recently, expression of Tie-2 was thought to be
restricted to endothelial cells, but in 2005 De Palma and
colleagues showed that a subpopulation of murine blood
monocytes expressing Tie-2 are recruited into spontaneous
murine and orthotopic human xenograft tumours and have a
crucial role in stimulating tumour angiogenesis [27]. We and
De Palma’s group have now extended these studies to show
that Tie-2+ monocytes are also abundant in human peripheral
blood and exist in a range of human tumours [28,29].
Moreover, Ang-2 was seen in both studies to act as a
powerful chemoattractant for these Tie-2+ monocytes in vitro
and is therefore highly likely to recruit Tie-2+ monocytes from
the bloodstream into tumours [28,29].
Our studies also demonstrated that hypoxia stimulates Tie-2
expression by human monocytes and macrophages [28],
suggesting that hypoxia may modulate the response of these
cells to Ang-2. Interestingly, several recent studies have
shown Ang-2 to be upregulated by tumour cells in hypoxic
areas of human tumours [30]. This means that it is highly
likely that TAMs would be exposed to both hypoxia and Ang-2
in such areas. This is important because we found that
exposure to hypoxia and Ang-2 had marked inhibitory effects
on the release of IL-12 by human Tie-2+ monocytes. This
suggests that when monocytes are recruited into tumours
and exposed to both Ang-2 and hypoxia it inhibits their ability
to mount an anti-angiogenic response. This, together with
their hypoxia-induced pro-angiogenic functions, would ensure
rapid angiogenesis in (and hence re-oxygenation of) the
avascular, hypoxic site.
Moreover, the combined action of Ang-2 and hypoxia also
inhibited the release of TNF-α by such cells [29]. This is
important because high-dose TNF-α is known to promote the
apoptosis of both tumour and endothelial cells [31], so its
downregulation near newly formed angiogenic blood vessels
could enhance tumour and endothelial cell survival and thus
promote metastasis and angiogenesis, respectively. Further-
more, high concentrations of TNF-α inhibit Ang-2 synthesis
by endothelial cells [32], so our data suggest that this
response of TAMs to Ang-2 may contribute to the high levels
of Ang-2 reported in breast tumours [25].
Conclusion
There is now undeniable evidence that macrophages drive
tumour angiogenesis and progression in certain murine
mammary tumour models, and this correlates well with
studies of their function in human breast tumours. Many
TAMs are found in hypoxic areas of such tissues where
unequivocal evidence has now been provided to show that
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Figure 2
Hypoxia induces marked changes in the phenotype of macrophages.
Macrophages upregulate hypoxia-inducible transcription factor (HIF)-1
and HIF-2 in hypoxia, which translocate to the nucleus to induce the
expression of a wide array of target genes. Several important cell-
surface receptors are upregulated in hypoxia, including the glucose
receptor GLUT-1 (for increased glucose uptake as the cell switches to
anaerobic glycolysis to make ATP in the absence of oxygen), the
chemokine stromal cell-derived factor-1 (SDF-1) receptor CXCR4, and
the angiopoietin receptor Tie-2. Hypoxia also stimulates the expression
of a wide array of other pro-tumour cytokines, enzymes and receptors,
grouped here according to their known function in tumours.
Downregulation of a factor or tumour-associated macrophage function
is indicated by an arrow [15,17,18]. Ag, antigen; COX, cyclo-
oxygenase; FGF, fibroblast growth factor; HGF, hepatocyte growth
factor; MIF, macrophage migration inhibitory factor; MMP, matrix
metalloproteinase; PDGF, platelet-derived growth factor; PGE2,
prostaglandin E2; TF, tissue factor; uPA/R, urokinase plasminogen
activator receptor; VEGF, vascular endothelial growth factor.hypoxia has profound effects on their function, stimulating
them to produce a wide array of pro-tumour growth factors,
cytokines and enzymes. Furthermore, hypoxia-induced
cytokines such as Ang-2 produced with the tumour
microenvironment seem to amplify the effects of hypoxia on
TAMs. It is hoped that present attempts to unearth the
signalling pathways mediating the powerful effects of hypoxia
and Ang-2 on these cells will highlight new targets for new
anti-cancer strategies.
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